DexCom Short-term marketable securities increased by 20.0% to $1.30B in Q1 2026 compared to the prior quarter.
An increase indicates the company is effectively managing excess cash to generate interest income, while a decrease may signal cash usage for operations.
These are short-term investments in debt securities that the company intends to hold for less than a year but are not cl...
Common among mature medical device firms that generate consistent operating cash flow.
current_assets_debt_securities_available_for_sale_exclud_614e64| Q4 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|
| Value | $1.97B | $1.77B | $1.49B | $1.08B | $1.30B |
| QoQ Change | — | -10.3% | -16.0% | -27.3% | +20.0% |
| YoY Change | — | — | — | -45.2% | — |